Very minimal fluence photodynamic therapy for chronic central serous chorioretinopathy.
To describe the safety and efficacy of very minimal fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). Retrospective case series. Five patients with chronic CSC. Two had previously failed alternative therapies, and one was taking concomitant corticosteroids. Patients were treated with very minimal fluence PDT (12 J/cm(2), 150 mW/cm(2), for 80 seconds). Median follow-up time after PDT was 100 days (range, 51 to 154). All patients experienced an improvement in visual acuity and symptoms, as well as complete resolution of subretinal fluid. Very minimal fluence PDT appears to be a safe and effective treatment for chronic CSC. Based on these preliminary findings, a randomized controlled trial is warranted.